OKYO Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101
OKYO Pharma is set to begin a Phase 2 clinical trial of OK-101 for treating neuropathic corneal pain (NCP) in Q3 2024. This is the first instance of an FDA IND clearance for a drug targeting NCP, a significant unmet medical need. OK-101 has shown statistically significant pain relief in previous trials for dry eye disease and preclinical models of NCP. The 12-week, placebo-controlled trial will be led by Dr. Pedram Hamrah at Tufts Medical Center, involving 48 NCP patients. The study aims to measure pain improvement using a visual analogue scale (VAS).
CEO Dr. Gary S. Jacob emphasizes the potential of OK-101, highlighting its previous success in reducing pain in dry eye patients, some of whom suffer from NCP. The trial's design includes five study visits over 16 weeks, with pain improvement as the primary endpoint. Encouraging preclinical and clinical data support the trial's objectives. More details are available in the company's Form 6-K filing.
- OK-101 received FDA IND clearance, the first for a drug targeting NCP.
- Statistically significant pain relief was observed in previous Phase 2 trials for dry eye disease.
- Preclinical mouse models showed OK-101 effectively reduced neuropathic corneal pain.
- The Phase 2 trial design includes a robust, double-masked, randomized, placebo-controlled methodology.
- The trial is led by an expert in NCP, Dr. Pedram Hamrah, enhancing its credibility.
- Previous trials indicated durable improvements in pain, vision, and burning/stinging symptoms.
- The trial is only starting in Q3 2024, delaying potential market availability.
- Results from preclinical models may not fully translate to human trials.
- The single-center study could limit the generalizability of the findings.
Insights
The announced Phase 2 clinical trial for OK-101 targeting neuropathic corneal pain (NCP) is a significant step in addressing a major unmet medical need. Neuropathic corneal pain is a rare and painful condition with no FDA-approved treatments to date, making this trial particularly noteworthy. The fact that OK-101 has already shown statistically significant pain relief in a previous trial for dry eye disease (DED) adds credibility to its potential effectiveness. Furthermore, the study's design, which includes a 12-week, double-masked, randomized, placebo-controlled format, is rigorous and should provide robust data on the drug's efficacy.
What stands out is the role of Dr. Pedram Hamrah, a leading expert in NCP and co-inventor of OK-101, as the Principal Investigator. His involvement adds a layer of expertise and assurance regarding the study's design and conduct. Given the FDA's clearance for the study, stakeholders can be cautiously optimistic about the potential for OK-101 to fill a significant therapeutic gap.
If the trial demonstrates significant pain relief, OKYO Pharma could gain a strong foothold in a niche but critical market. Investors should monitor patient enrollment and interim results closely. While the initial data is promising, the true test will be the Phase 2 trial outcomes.
From a financial perspective, the initiation of this Phase 2 trial for OK-101 could have substantial implications for OKYO Pharma. Given that NCP is classified as an orphan disease, it offers the company potential benefits like tax credits, market exclusivity and grants, which could enhance profitability and reduce the financial risks associated with drug development. The multi-billion-dollar market for inflammatory dry eye disease and related conditions provides a lucrative opportunity if OK-101 proves effective.
However, investors should be wary of the inherent risks associated with clinical trials. While preclinical models and previous human trials show promise, the financial health of OKYO Pharma will be closely tied to the successful execution and outcomes of this study. Also, it's important to pay attention to the company's cash burn rate and funding capabilities during this period. A positive outcome could significantly boost the company's valuation and attract partnerships or acquisition interest.
The market outlook for OK-101 could be transformative for OKYO Pharma. Neuropathic corneal pain is a condition that has been underserved and the absence of FDA-approved therapies means there is a ready market for effective treatment. OK-101's initial data showing statistically significant pain relief is promising, but market acceptance will depend on the results of the upcoming Phase 2 trial. If successful, OKYO Pharma could be first-to-market for NCP treatment, a significant competitive advantage.
Investors should also consider the broader market for ocular therapies. OKYO Pharma's focus on not just NCP but also dry eye disease and other anterior ocular segment diseases positions them well to capture a significant market share. Trends in increasing prevalence of these conditions globally, especially in aging populations, further underscore the potential market demand.
Nevertheless, it's essential to maintain a cautious approach until more concrete data from the trial are available. The competitive landscape, potential regulatory hurdles and real-world efficacy will ultimately determine the market success of OK-101.
- Phase 2 randomized, placebo-controlled trial in neuropathic corneal pain (NCP) patients planned to begin in Q3, 2024
- OK-101 is believed to be the first IND clearance granted by FDA for a drug to begin clinical studies specifically to treat patients suffering with neuropathic corneal pain (NCP), a major unmet medical need
- OK-101 demonstrated statistically significant pain relief as measured by visual analogue scale (VAS) from Day 29 through the last study visit at Day 85 in a Phase 2 trial of dry eye disease, as well as reduced neuropathic corneal pain (NCP) in a preclinical mouse model
- NCP is an Orphan disease as listed in the National Organization for Rare Disorders
LONDON and NEW YORK, July 11, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, announced today its plan to advance OK-101 into a Phase 2 clinical trial of neuropathic corneal pain which is expected to begin in Q3 2024. This one-year study is supported by pre-clinical animal model data and statistically significant pain relief observed in OK-101’s first human trial recently conducted in DED patients.
The Phase 2 NCP trial will be conducted at a single-center and will be led by Pedram Hamrah, MD, of Tufts Medical Center, as Principal Investigator. Dr. Hamrah is Professor and Vice Chair of Research and Academic Programs, Director of the Cornea Service and Director of the Center for Translational Ocular Immunology at Tufts Medical Center. An ophthalmologist and a clinician-scientist, Dr. Hamrah is a leading expert in NCP and co-inventor on the OK-101 patent. He is also a member of OKYO’s Scientific Advisory Board.
“I am looking forward to rigorously evaluating OK-101’s potential in treating pain symptoms in patients suffering from neuropathic corneal pain,” said Dr. Hamrah. “We have designed an effective protocol to test our hypothesis in this patient population after productive FDA interactions and we will be closely overseeing the conduct of this trial at Tufts Medical Center.”
“We believe that OK-101 is the first NCP drug candidate to have received FDA IND clearance for clinical evaluation and are pleased to be making rapid progress to advance the NCP program while working to refine the study design for our upcoming trial in DED,” said Dr. Gary S. Jacob, Ph.D., CEO of OKYO. “The favorable improvements in ocular pain in dry eye patients, a percentage of whom suffer from NCP, along with the impressive results from a preclinical model of NCP are encouraging signs as we look for a positive result in this upcoming Phase 2 trial in NCP. Notably, OK-101 targets a receptor found in neurons and glial cells. NCP is an acutely painful ocular disease with no FDA-approved therapy. We are hoping to deliver an exciting innovation to this ophthalmic unmet need.”
The Phase 2 NCP study is designed as a double-masked, randomized, 12-week placebo-controlled trial comparing OK-101 to placebo in 48 NCP patients whose disease has been diagnosed by confocal microscopy. The primary endpoint for the study is pain improvement measured by VAS compared to placebo. There will be a total of five study visits over the course of 16 weeks, which includes a follow-up visit four weeks after completion.
In a recently completed Phase 2 trial of DED patients, there was a statistically significant and durable improvement in pain, blurred vision, and burning/stinging as measured by VAS beginning on Day 29, Day 15 and Day 15, respectively, and through the last study visit at Day 85. Additionally, there was a significant improvement in pain scores as measured by patient reported daily diaries observed as early as within the first two weeks of treatment and through the last study visit at Day 85. Furthermore, in a preclinical mouse model, OK-101 reduced corneal pain response comparably to gabapentin on Day 14 post-surgery. For additional details, please refer to the slides in the issued Form 6-K filing.
About NCP
Neuropathic corneal pain (NCP) is a condition that causes pain and sensitivity of the eyes, face, or head. The exact cause of NCP is unknown but thought to result from nerve damage to the cornea combined with inflammation. NCP, which can exhibit as a severe, chronic, or debilitating condition in patients suffering from a host of ophthalmic conditions, is presently treated by various topical and systemic treatments in an off-label fashion. There are no approved commercial treatments currently available for this condition.
About OK-101
OK-101 is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response. OK-101 was developed using a membrane-anchored-peptide technology to produce a novel long-acting drug candidate for treating dry eye disease. OK-101 has been shown to produce anti-inflammatory and pain-reducing efficacy signals in mouse models of dry eye disease and corneal neuropathic pain (NCP), respectively, and is designed to combat washout through the inclusion of the lipid anchor built into the drug molecule to enhance the residence time of OK-101 within the ocular environment. OK-101 recently showed statistical significance in multiple endpoints in a recently completed Phase 2, multi-center, double-blind, placebo-controlled trial of OK-101 to treat DED.
About OKYO
OKYO Pharma Limited (NASDAQ: OKYO) is a clinical stage biopharmaceutical company developing innovative therapies for the treatment of DED and NCP, with ordinary shares listed for trading on the NASDAQ Capital Market. OKYO is focused on the discovery and development of novel molecules to treat inflammatory DED and ocular pain. In addition to the recently completed Phase 2 DED trial, OKYO also has plans underway for the opening of a Phase 2 trial for OK-101 to treat NCP in patients with this debilitating condition. For further information, please visit www.okyopharma.com.
Forward-Looking Statements
Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections about its industry, its beliefs, and assumptions. Words such as ‘anticipates,’ ‘expects,’ ‘intends,’ ‘plans,’ ‘believes,’ ‘seeks,’ ‘estimates,’ and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company’s control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. These and additional risks and uncertainties are described more fully in the company’s filings with the SEC, including those factors identified as “Risk Factors” in our most recent Annual Report on Form 20-F, for the fiscal year ended March 31, 2023. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.
Enquiries:
| OKYO Pharma Limited | Gary S. Jacob, Chief Executive Officer | 917-497-7560 |
| Business Development & Investor Relations | Paul Spencer | +44 (0)20 7495 2379 |
FAQ
When will OKYO Pharma's Phase 2 trial for OK-101 begin?
What is the primary endpoint for OKYO Pharma's Phase 2 trial of OK-101?
What previous results support OKYO Pharma's upcoming trial for OK-101?
Who is leading the Phase 2 trial for OKYO Pharma's OK-101?
How long will OKYO Pharma's Phase 2 trial for OK-101 last?
What makes OK-101 significant in treating neuropathic corneal pain?
